Sequence-specific alterations of epitope production by HIV protease inhibitors

Journal of Immunology

Volumn 192, Issue 8, 2014, Pages 3496-3506

  Kourjian, Georgio ^a   Xu, Yang ^a   Mondesire Crump, Ijah ^a   Shimada, Mariko ^a   Gourdain, Pauline ^a   Le Gall, Sylvie ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID SEQUENCE; AMINOPEPTIDASES; ANTIGEN PRESENTATION; CD8-POSITIVE T-LYMPHOCYTES; ENZYME ACTIVATION; EPITOPES, T-LYMPHOCYTE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INTRACELLULAR SPACE; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN STABILITY; PROTEOLYSIS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84898669958     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1302805     Document Type: Article

References (81)

1. Autran, B., G. Carcelain, T. S. Li, C. Blanc, D. Mathez, R. Tubiana, C. Katlama, P. Debré, and J. Leibowitch. 1997. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 277: 112-116.
2. Flexner, C. 1998. HIV-protease inhibitors. N. Engl. J. Med. 338: 1281-1292.
3. Fernández-Montero, J. V., P. Barreiro, and V. Soriano. 2009. HIV protease inhibitors: recent clinical trials and recommendations on use. Expert Opin. Pharmacother. 10: 1615-1629.
4. Carr, A., K. Samaras, S. Burton, M. Law, J. Freund, D. J. Chisholm, and D. A. Cooper. 1998. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 12: F51-F58.
5. Ena, J., C. Benito, P. Llácer, F. Pasquau, and C. Amador. 2004. [Abnormal body fat distribution and type of antiretroviral therapy as predictors of cardiovascular disease risk in HIV-infected patients]. Med. Clin. (Barc.) 122: 721-726.
6. Yarasheski, K. E., P. Tebas, C. Sigmund, S. Dagogo-Jack, A. Bohrer, J. Turk, P. A. Halban, P. E. Cryer, and W. G. Powderly. 1999. Insulin resistance in HIV protease inhibitor-associated diabetes. J. Acquir. Immune Defic. Syndr. 21: 209-216.
7. Brown, T. T., and R. B. Qaqish. 2006. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 20: 2165-2174.
8. Boesecke, C., and D. A. Cooper. 2008. Toxicity of HIV protease inhibitors: clinical considerations. Curr. Opin. HIV AIDS 3: 653-659.
9. Orkin, C., E. DeJesus, H. Khanlou, A. Stoehr, K. Supparatpinyo, E. Lathouwers, E. Lefebvre, M. Opsomer, T. Van de Casteele, and F. Tomaka. 2013. Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naive patients in the ARTEMIS trial. HIV Med. 14: 49-59.
10. Erickson, J., D. J. Neidhart, J. VanDrie, D. J. Kempf, X. C. Wang, D.W. Norbeck, J. J. Plattner, J.W. Rittenhouse, M. Turon, N.Wideburg, et al. 1990. Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease. Science 249: 527-533.
11. Diez-Rivero, C. M., E. M. Lafuente, and P. A. Reche. 2010. Computational analysis and modeling of cleavage by the immunoproteasome and the constitutive proteasome. BMC Bioinformatics 11: 479.
12. Goldberg, A. L. 2003. Protein degradation and protection against misfolded or damaged proteins. Nature 426: 895-899.
13. York, I. A., A. X. Mo, K. Lemerise, W. Zeng, Y. Shen, C. R. Abraham, T. Saric, A. L. Goldberg, and K. L. Rock. 2003. The cytosolic endopeptidase, thimet oligopeptidase, destroys antigenic peptides and limits the extent of MHC class I antigen presentation. Immunity 18: 429-440.
14. Saric, T., C. I. Graef, and A. L. Goldberg. 2004. Pathway for degradation of peptides generated by proteasomes: a key role for thimet oligopeptidase and other metallopeptidases. J. Biol. Chem. 279: 46723-46732.
15. Kawahara, M., I. A. York, A. Hearn, D. Farfan, and K. L. Rock. 2009. Analysis of the role of tripeptidyl peptidase II in MHC class I antigen presentation in vivo. J. Immunol. 183: 6069-6077.
16. Serwold, T., F. Gonzalez, J. Kim, R. Jacob, and N. Shastri. 2002. ERAAP customizes peptides for MHC class I molecules in the endoplasmic reticulum. Nature 419: 480-483.
17. York, I. A., S. C. Chang, T. Saric, J. A. Keys, J. M. Favreau, A. L. Goldberg, and K. L. Rock. 2002. The ER aminopeptidase ERAP1 enhances or limits antigen presentation by trimming epitopes to 8-9 residues. Nat. Immunol. 3: 1177-1184.
18. Lazaro, E., C. Kadie, P. Stamegna, S. C. Zhang, P. Gourdain, N. Y. Lai, M. Zhang, S. A. Martinez, D. Heckerman, and S. Le Gall. 2011. Variable HIV peptide stability in human cytosol is critical to epitope presentation and immune escape. J. Clin. Invest. 121: 2480-2492.
19. Herberts, C. A., J. J. Neijssen, J. de Haan, L. Janssen, J. W. Drijfhout, E. A. Reits, and J. J. Neefjes. 2006. Cutting edge: HLA-B27 acquires many N-terminal dibasic peptides: coupling cytosolic peptide stability to antigen presentation. J. Immunol. 176: 2697-2701.
20. Reits, E., A. Griekspoor, J. Neijssen, T. Groothuis, K. Jalink, P. van Veelen, H. Janssen, J. Calafat, J. W. Drijfhout, and J. Neefjes. 2003. Peptide diffusion, protection, and degradation in nuclear and cytoplasmic compartments before antigen presentation by MHC class I. Immunity 18: 97-108.
21. Kisselev, A. F., T. N. Akopian, K. M. Woo, and A. L. Goldberg. 1999. The sizes of peptides generated from protein by mammalian 26 and 20 S proteasomes. Implications for understanding the degradative mechanism and antigen presentation. J. Biol. Chem. 274: 3363-3371.
22. Hearn, A., I. A. York, and K. L. Rock. 2009. The specificity of trimming of MHC class I-presented peptides in the endoplasmic reticulum. J. Immunol. 183: 5526-5536.
23. Schatz, M. M., B. Peters, N. Akkad, N. Ullrich, A. N. Martinez, O. Carroll, S. Bulik, H. G. Rammensee, P. van Endert, H. G. Holzhutter, et al. 2008. Characterizing the N-terminal processing motif of MHC class I ligands. J. Immunol. 180: 3210-3217.
24. Zhang, S. C., E. Martin, M. Shimada, S. B. Godfrey, J. Fricke, S. Locastro, N. Y. Lai, P. Liebesny, J. M. Carlson, C. J. Brumme, et al. 2012. Aminopeptidase substrate preference affects HIV epitope presentation and predicts immune escape patterns in HIV-infected individuals. J. Immunol. 188: 5924-5934.
25. Le Gall, S., P. Stamegna, and B. D. Walker. 2007. Portable flanking sequences modulate CTL epitope processing. J. Clin. Invest. 117: 3563-3575.
26. Lazaro, E., S. B. Godfrey, P. Stamegna, T. Ogbechie, C. Kerrigan, M. Zhang, B. D. Walker, and S. Le Gall. 2009. Differential HIV epitope processing in monocytes and CD4 T cells affects cytotoxic T lymphocyte recognition. J. Infect. Dis. 200: 236-243.
27. Rock, K. L., C. Gramm, L. Rothstein, K. Clark, R. Stein, L. Dick, D. Hwang, and A. L. Goldberg. 1994. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 78: 761-771.
28. York, I. A., M. A. Brehm, S. Zendzian, C. F. Towne, and K. L. Rock. 2006. Endoplasmic reticulum aminopeptidase 1 (ERAP1) trims MHC class I-presented peptides in vivo and plays an important role in immunodominance. Proc. Natl. Acad. Sci. USA 103: 9202-9207.
29. Blanchard, N., T. Kanaseki, H. Escobar, F. Delebecque, N. A. Nagarajan, E. Reyes-Vargas, D. K. Crockett, D. H. Raulet, J. C. Delgado, and N. Shastri. 2010. Endoplasmic reticulum aminopeptidase associated with antigen processing defines the composition and structure of MHC class I peptide repertoire in normal and virus-infected cells. J. Immunol. 184: 3033-3042.
30. André, P., M. Groettrup, P. Klenerman, R. de Giuli, B. L. Booth, Jr., V. Cerundolo, M. Bonneville, F. Jotereau, R. M. Zinkernagel, and V. Lotteau. 1998. An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses. Proc. Natl. Acad. Sci. USA 95: 13120-13124.
31. Gaedicke, S., E. Firat-Geier, O. Constantiniu, M. Lucchiari-Hartz, M. Freudenberg, C. Galanos, and G. Niedermann. 2002. Antitumor effect of the human immunodeficiency virus protease inhibitor ritonavir: induction of tumor-cell apoptosis associated with perturbation of proteasomal proteolysis. Cancer Res. 62: 6901-6908.
32. Kelleher, A. D., B. L. Booth, Jr., A. K. Sewell, A. Oxenius, V. Cerundolo, A. J. McMichael, R. E. Phillips, and D. A. Price. 2001. Effects of retroviral protease inhibitors on proteasome function and processing of HIV-derived MHC class I-restricted cytotoxic T lymphocyte epitopes. AIDS Res. Hum. Retroviruses 17: 1063-1066.
33. Piccinini, M., M. T. Rinaudo, A. Anselmino, B. Buccinná, C. Ramondetti, A. Dematteis, E. Ricotti, L. Palmisano, M. Mostert, and P. A. Tovo. 2005. The HIV protease inhibitors nelfinavir and saquinavir, but not a variety of HIV reverse transcriptase inhibitors, adversely affect human proteasome function. Antivir. Ther. (Lond.) 10: 215-223.
34. Pajonk, F., J. Himmelsbach, K. Riess, A. Sommer, and W. H. McBride. 2002. The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIVassociated human cancer cells. Cancer Res. 62: 5230-5235.
35. Hill, A., A. McBride, A. W. Sawyer, N. Clumeck, and R. K. Gupta. 2013. Resistance at virological failure using boosted protease inhibitors versus nonnucleoside reverse transcriptase inhibitors as first-line antiretroviral therapy-implications for sustained efficacy of ART in resource-limited settings. J. Infect. Dis. 207(Suppl. 2): S78-S84.
36. Hosseinipour, M. C., R. K. Gupta, G. Van Zyl, J. J. Eron, and J. B. Nachega. 2013. Emergence of HIV drug resistance during first-and second-line antiretroviral therapy in resource-limited settings. J. Infect. Dis. 207(Suppl. 2): S49-S56.
37. Kisselev, A. F., and A. L. Goldberg. 2005. Monitoring activity and inhibition of 26S proteasomes with fluorogenic peptide substrates. Methods Enzymol. 398: 364-378.
38. Gourdain, P., J. Boucau, G. Kourjian, N. Y. Lai, E. Duong, and S. Le Gall. 2013. A real-time killing assay to follow viral epitope presentation to CD8 T cells. J. Immunol. Methods 398-399: 60-67.
39. Acosta, E. P., T. N. Kakuda, R. C. Brundage, P. L. Anderson, and C. V. Fletcher. 2000. Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors. Clin. Infect. Dis. 30(Suppl. 2): S151-S159.
40. Cardiello, P. G., T. Monhaphol, A. Mahanontharit, R. P. van Heeswijk, D. Burger, A. Hill, K. Ruxrungtham, J. M. Lange, D. A. Cooper, and P. Phanuphak. 2003. Pharmacokinetics of once-daily saquinavir hard-gelatin capsules and saquinavir softgelatin capsules boosted with ritonavir in HIV-1-infected subjects. J. Acquir. Immune Defic. Syndr. 32: 375-379.
41. Hennessy, M., S. Clarke, J. P. Spiers, D. Kelleher, F. Mulcahy, P. Hoggard, D. Back, and M. Barry. 2004. Intracellular accumulation of nelfinavir and its relationship to P-glycoprotein expression and function in HIV-infected patients. Antivir. Ther. (Lond.) 9: 115-122.
42. Jackson, A., V. Watson, D. Back, S. Khoo, N. Liptrott, D. Egan, K. Gedela, C. Higgs, R. Abbas, B. Gazzard, and M. Boffito. 2011. Plasma and intracellular pharmacokinetics of darunavir/ritonavir once daily and raltegravir once and twice daily in HIV-infected individuals. J. Acquir. Immune Defic. Syndr. 58: 450-457.
43. van Heeswijk, R. P., A. I. Veldkamp, J. W. Mulder, P. L. Meenhorst, J. M. Lange, J. H. Beijnen, and R. M. Hoetelmans. 2000. Once-daily dosing of saquinavir and low-dose ritonavir in HIV-1-infected individuals: a pharmacokinetic pilot study. AIDS 14: F103-F110.
44. Reits, E., J. Neijssen, C. Herberts, W. Benckhuijsen, L. Janssen, J. W. Drijfhout, and J. Neefjes. 2004. A major role for TPPII in trimming proteasomal degradation products for MHC class I antigen presentation. Immunity 20: 495-506.
45. Frahm, N., B. Baker, and C. Brander. 2008. Identification and optimal definition of HIV-derived cytotoxic T lymphocyte (CTL) epitopes for the study of CTL escape, functional avidity and viral evolution. In HIV Molecular Immunology 2008. B. T. Korber, C. Brander, and B. F. Haynes, et al., eds. Los Alamos National Laboratory, Los Alamos, NM, p. 1-24.
46. Batchelor, R. H., and M. Zhou. 2004. Use of cellular glucose-6-phosphate dehydrogenase for cell quantitation: applications in cytotoxicity and apoptosis assays. Anal. Biochem. 329: 35-42.
47. Rosenblum, J. S., and J. W. Kozarich. 2003. Prolyl peptidases: a serine protease subfamily with high potential for drug discovery. Curr. Opin. Chem. Biol. 7: 496-504.
48. Schmidtke, G., H. G. Holzhutter, M. Bogyo, N. Kairies, M. Groll, R. de Giuli, S. Emch, and M. Groettrup. 1999. How an inhibitor of the HIV-I protease modulates proteasome activity. J. Biol. Chem. 274: 35734-35740.
49. Sato, A., T. Asano, K. Ito, and T. Asano. 2012. Ritonavir interacts with bortezomib to enhance protein ubiquitination and histone acetylation synergistically in renal cancer cells. Urology 79:966.e13-21.
50. Ruschak, A. M., and L. E. Kay. 2012. Proteasome allostery as a population shift between interchanging conformers. Proc. Natl. Acad. Sci. USA 109: E3454-E3462.
51. Jankowska, E., M. Gaczynska, P. Osmulski, E. Sikorska, R. Rostankowski, S. Madabhushi, M. Tokmina-Lukaszewska, and F. Kasprzykowski. 2010. Potential allosteric modulators of the proteasome activity. Biopolymers 93: 481-495.
52. Kisselev, A. F., T. N. Akopian, V. Castillo, and A. L. Goldberg. 1999. Proteasome active sites allosterically regulate each other, suggesting a cyclical bitechew mechanism for protein breakdown. Mol. Cell 4: 395-402.
53. Spector, A. A. 2006. HIV protease inhibitors and hyperlipidemia: a fatty acid connection. Arterioscler. Thromb. Vasc. Biol. 26: 7-9.
54. Anuurad, E., A. Bremer, and L. Berglund. 2010. HIV protease inhibitors and obesity. Curr. Opin. Endocrinol. Diabetes Obes. 17: 478-485.
55. Noor, M. A., O. P. Flint, J. F. Maa, and R. A. Parker. 2006. Effects of atazanavir/ ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically. AIDS 20: 1813-1821.
56. Waring, J. F., R. Ciurlionis, K. Marsh, L. L. Klein, D. A. Degoey, J. T. Randolph, B. Spear, and D. J. Kempf. 2010. Identification of proteasome gene regulation in a rat model for HIV protease inhibitor-induced hyperlipidemia. Arch. Toxicol. 84: 263-270.
57. Lum, P. Y., Y. D. He, J. G. Slatter, J. F. Waring, N. Zelinsky, G. Cavet, X. Dai, O. Fong, R. Gum, L. Jin, et al. 2007. Gene expression profiling of rat liver reveals a mechanistic basis for ritonavir-induced hyperlipidemia. Genomics 90: 464-473.
58. Meiners, S., D. Heyken, A. Weller, A. Ludwig, K. Stangl, P. M. Kloetzel, and E. Kruger. 2003. Inhibition of proteasome activity induces concerted expression of proteasome genes and de novo formation of Mammalian proteasomes. J. Biol. Chem. 278: 21517-21525.
59. Riddle, T. M., D. G. Kuhel, L. A. Woollett, C. J. Fichtenbaum, and D. Y. Hui. 2001. HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus. J. Biol. Chem. 276: 37514-37519.
60. Kramer, W., F. Girbig, D. Corsiero, A. Pfenninger, W. Frick, G. Jähne, M. Rhein, W. Wendler, F. Lottspeich, E. O. Hochleitner, et al. 2005. Aminopeptidase N (CD13) is a molecular target of the cholesterol absorption inhibitor ezetimibe in the enterocyte brush border membrane. J. Biol. Chem. 280: 1306-1320.
61. Levy, E., S. Spahis, D. Sinnett, N. Peretti, F. Maupas-Schwalm, E. Delvin, M. Lambert, and M. A. Lavoie. 2007. Intestinal cholesterol transport proteins: an update and beyond. Curr. Opin. Lipidol. 18: 310-318.
62. Yeh, T. Y., J. I. Sbodio, Z. Y. Tsun, B. Luo, and N. W. Chi. 2007. Insulinstimulated exocytosis of GLUT4 is enhanced by IRAP and its partner tankyrase. Biochem. J. 402: 279-290.
63. Thornberry, N. A., T. A. Rano, E. P. Peterson, D. M. Rasper, T. Timkey, M. Garcia-Calvo, V. M. Houtzager, P. A. Nordstrom, S. Roy, J. P. Vaillancourt, et al. 1997. A combinatorial approach defines specificities of members of the caspase family and granzyme B. Functional relationships established for key mediators of apoptosis. J. Biol. Chem. 272: 17907-17911.
64. Feeney, M. E., Y. Tang, K. Pfafferott, K. A. Roosevelt, R. Draenert, A. Trocha, X. G. Yu, C. Verrill, T. Allen, C. Moore, et al. 2005. HIV-1 viral escape in infancy followed by emergence of a variant-specific CTL response. J. Immunol. 174: 7524-7530.
65. Allen, T. M., X. G. Yu, E. T. Kalife, L. L. Reyor, M. Lichterfeld, M. John, M. Cheng, R. L. Allgaier, S. Mui, N. Frahm, et al. 2005. De novo generation of escape variant-specific CD8+ T-cell responses following cytotoxic T-lymphocyte escape in chronic human immunodeficiency virus type 1 infection. J. Virol. 79: 12952-12960.
66. O'Connell, K. A., R. W. Hegarty, R. F. Siliciano, and J. N. Blankson. 2011. Viral suppression of multiple escape mutants by de novo CD8(+) T cell responses in a human immunodeficiency virus-1 infected elite suppressor. Retrovirology 8: 63.
67. Turnbull, E. L., M. Wong, S. Wang, X. Wei, N. A. Jones, K. E. Conrod, D. Aldam, J. Turner, P. Pellegrino, B. F. Keele, et al. 2009. Kinetics of expansion of epitope-specific T cell responses during primary HIV-1 infection. J. Immunol. 182: 7131-7145.
68. Liu, M. K., N. Hawkins, A. J. Ritchie, V. V. Ganusov, V. Whale, S. Brackenridge, H. Li, J. W. Pavlicek, F. Cai, M. Rose-Abrahams, et al; CHAVI Core B. 2013. Vertical T cell immunodominance and epitope entropy determine HIV-1 escape. J. Clin. Invest. 123: 380-393.
69. Borrow, P., H. Lewicki, X. Wei, M. S. Horwitz, N. Peffer, H. Meyers, J. A. Nelson, J. E. Gairin, B. H. Hahn, M. B. Oldstone, and G. M. Shaw. 1997. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat. Med. 3: 205-211.
70. Nowak, M. A., R. M. May, R. E. Phillips, S. Rowland-Jones, D. G. Lalloo, S. McAdam, P. Klenerman, B. Köppe, K. Sigmund, C. R. Bangham, et al. 1995. Antigenic oscillations and shifting immunodominance in HIV-1 infections. Nature 375: 606-611.
71. Archin, N. M., A. L. Liberty, A. D. Kashuba, S. K. Choudhary, J. D. Kuruc, A. M. Crooks, D. C. Parker, E. M. Anderson, M. F. Kearney, M. C. Strain, et al. 2012. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487: 482-485.
72. Siliciano, J. D., and R. F. Siliciano. 2013. HIV-1 eradication strategies: design and assessment. Curr. Opin. HIV AIDS 8: 318-325.
73. Jalali, Z., and J. K. Rockstroh. 2012. Antiviral drugs and the treatment of hepatitis C. Curr. HIV/AIDS Rep. 9: 132-138.
74. Naidoo, K., C. Baxter, and S. S. Abdool Karim. 2013. When to start antiretroviral therapy during tuberculosis treatment? Curr. Opin. Infect. Dis. 26: 35-42.
75. Walker, N. F., G. Meintjes, and R. J. Wilkinson. 2013. HIV-1 and the immune response to TB. Future Virol. 8: 57-80.
76. Bono, C., L. Karlin, S. Harel, E. Mouly, S. Labaume, L. Galicier, S. Apcher, H. Sauvageon, J. P. Fermand, J. C. Bories, and B. Arnulf. 2012. The human immunodeficiency virus-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the proliferation of multiple myeloma cells in vitro and in vivo. Haematologica 97: 1101-1109.
77. Kawabata, S., J. J. Gills, J. R. Mercado-Matos, J. Lopiccolo, W. Wilson, III, M. C. Hollander, and P. A. Dennis. 2012. Synergistic effects of nelfinavir and bortezomib on proteotoxic death of NSCLC and multiple myeloma cells. Cell Death Dis. 3: e353.
78. Kraus, M., E. Malenke, J. Gogel, H. Muller, T. Ruckrich, H. Overkleeft, H. Ovaa, E. Koscielniak, J. T. Hartmann, and C. Driessen. 2008. Ritonavir induces endoplasmic reticulum stress and sensitizes sarcoma cells toward bortezomibinduced apoptosis. Mol. Cancer Ther. 7: 1940-1948.
79. Sgadari, C., P. Monini, G. Barillari, and B. Ensoli. 2003. Use of HIV protease inhibitors to block Kaposi's sarcoma and tumour growth. Lancet Oncol. 4: 537-547.
80. Zeng, J., A. P. See, K. Aziz, S. Thiyagarajan, T. Salih, R. P. Gajula, M. Armour, J. Phallen, S. Terezakis, L. Kleinberg, et al. 2011. Nelfinavir induces radiation sensitization in pituitary adenoma cells. Cancer Biol. Ther. 12: 657-663.
81. Kimple, R. J., A. V. Vaseva, A. D. Cox, K. M. Baerman, B. F. Calvo, J. E. Tepper, J. M. Shields, and C. I. Sartor. 2010. Radiosensitization of epidermal growth factor receptor/HER2-positive pancreatic cancer is mediated by inhibition of Akt independent of ras mutational status. Clin. Cancer Res. 16: 912-923.